United States Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The US drug delivery devices market is expected to register a CAGR of 22.78% during the forecast period.

COVID-19 had a significant impact on the market studied during the early stages due to the rise in vaccination and immunization which utilized syringes and needles for administering the vaccines. As researchers developed vaccinations against COVID-19 that were widely administered intravenously, utilizing the syringe as a drug delivery device. As per the article published in 2022 by Drug Delivery and Translational Research journal, the success of mRNA vaccines demonstrated the critical role that drug delivery technologies had played in protecting billions of people from SARS-CoV-2. Administration of mRNA vaccines across the globe rise the demand for syringes as drug delivery devices, thereby increasing the market growth. As per the same source, the current mRNA development of COVID-19 vaccines is the outcome of years of basic research in the disciplines of nucleic acid therapy and drug delivery. Hence, an increase in research and development activities during and post-pandemic periods is expected to lead to growth in the post-pandemic period.

Factors such as the growing burden of chronic diseases and the developments related to drug delivery methods are expected to significantly contribute to the market growth. According to the 2022 data from the CDC, about six out of ten American individuals are suffering from chronic diseases, which are leading drivers of the nation’s annual healthcare costs, amounting to around USD 4.1 trillion. Changing lifestyles, such as physical inactivity, consumption of a high-sugar diet, alcohol, smoking, etc., are responsible for the growing burden of the disease in the United States. As per the same source, physical inactivity ranges from 17.3 to 47.7 in the country. Thus, it is expected to drive the need for the management of these diseases, thereby boosting the market.

Product launches and collaboration in the United States regarding the market are likely to boost the market growth. In May 2022, Gland Pharma launched the cancer treatment drug Bortezomib, in an injection form, in the US market. The company launched the product in the US market through its partner, which received approval from the FDA. Bortezomib Injection is used to treat cancers, such as multiple myeloma and mantle cell lymphoma. Furthermore, in November 2022, Medtronic plc launched the Medtronic Extended infusion set, the first and only infusion set labeled for up to 7-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days. Hence, considering the increased product launches in the United States, the drug delivery market is likely to grow over the forecast period.

Thus, due to the rise in the burden of chronic diseases and the increase in product launches, the market is anticipated to witness growth over the forecast period. However, the recalling of products by the FDA is expected to impede the market growth.

USA Drug Delivery Devices Market Trends

Cancer Segment is Expected to Hold a Major Market Share in the United States Drug Delivery Devices Market

The cancer segment is expected to hold a significant share of the market studied. According to the ACS 2022 update, the number of new cancer cases is estimated to be 1.9 million in the United States in 2022. As per NCI, prostate, lung, and colorectal cancers accounted for an estimated 43% of all cancers diagnosed in men in 2020. For women, the three most common cancers are breast, lung, and colorectal; they accounted for 50% of all new cancer diagnoses in women in 2020. Hence, the high prevalence of cancer cases in the United States is likely to boost the market growth.

There is an immense need for a better delivery system in the treatment of cancer to improve the outcome. Recent developments concerning the drug delivery system in cancer are further expected to accelerate market growth. For instance, as per the August 2022 press release by the USFDA, the FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer. This is the first approved therapy for patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer. Furthermore, increased government initiatives and funds to improve cancer drug delivery in the United States are boosting the market growth. For instance, as per the report of the NCI Budget 2022, the budget proposal included USD 50 million for the Childhood Cancer Data Initiative, as well as Cancer MoonshotSM funding, which was authorized in the 21st Century, Cures Act.

Thus, due to the growing burden of cancer cases, and the increase in healthcare expenditure the cancer segment is expected to record significant growth during the forecast period.

Injectable Segment is Anticipated to Witness Significant Growth Over the Forecast Period

The injectable segment is likely to observe significant growth in the market studied owing to factors such as an increase in vaccination and immunization in the country and the presence of a large patient population suffering from various chronic diseases. For instance, according to the WHO immunization data portal, the diphtheria-containing vaccine's fourth dosage (first booster) was administered to 81.6% of the population. With the increase in immunization, the utilization of syringes and needles also increases, which is expected to boost the segment's growth over the forecast period.

Furthermore, in June 2022, BD (Becton, Dickinson, and Co.) and Mitsubishi Gas Chemical Co. Inc. (MCG) signed a letter of intent to discuss a partnership to explore new ways to advance pre-fillable syringe technology for biologic drug delivery. The agreement stated that they are anticipated to investigate the development of Oxycapt, an innovation from MGC that integrates the best of plastic and glass for the plastic syringe.

The increased adoption of injectable drugs, technological advancements in syringes, and the growing number of vaccination and immunization programs are expected to drive the volume growth over the next few years. For instance, in January 2022, Nephron Pharmaceuticals Corporation launched the cyclic olefin copolymer syringe (COC). It has a glass-like appearance but is break-resistant and lightweight. COC syringes are suitable for a variety of medications, including highly viscous drugs, and provide an extended product shelf-life. The disconnected plunger allows for easier storage. Also, the expansion of facilities to produce syringes is anticipated to contribute to the growth of the market.

Hence, due to the rise in injectable product launches and the increase in vaccination coverage, the injectable segment is anticipated to witness growth over the forecast period.

USA Drug Delivery Devices Market Competitor Analysis

The US drug delivery devices market is highly competitive. The competitive landscape includes an analysis of a few international as well as local companies that hold market shares and are well known. Many of these companies are undertaking various strategies to maintain their market shares. The key players in the market are Bayer AG, Johnson & Johnson Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Merck & Co. Inc., Sanofi, Abbott Laboratories, and 3M.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.